A group of investors including The Halifax Group and SV Life Sciences announced a series of acquisitions that are an integral part of its strategy to build a global differentiated biopharmaceutical services company.
Led by Patrick K. Donnelly, one of the investors and former CEO of PRA International, the investment group purchased all shares of ClinResearch and ADDPLAN, global leaders in adaptive trial services and software, and Fulcrum Pharma, a UK-based company that provides comprehensive drug development, regulatory and safety services.
“With these announcements, and our previous partnership with Trio Clinical Research, we can now offer clients around the world access to innovative, comprehensive and proven development capabilities,” Mr. Donnelly said. “With the constant pressures and challenges currently facing the drug industry, we need to approach drug and device development from a different and more dynamic paradigm.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.